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Abstract: 
Nasopharyngeal carcinoma (NPC) is a malignant tumor in the nasopharyngeal epithelial cells that caused by many factors, one of 
which is the viral infection of EBV (Epstein Barr Virus). The standard treatments to cure NPC still have not been encouraging. The 
prevention through vaccination is an effective way to stop the disease. However, EBV vaccine being able to cover all variants of 
virus is still not available yet. Therefore, we identified the conserved region of glycoprotein 350/220 of EBV which has 
immunogenic and antigenic properties.  The glycoprotein 350/220 is viral surface protein responsible to bind CR2 receptor, 
mediated EBV to enter the host cell. The conserved domain is crucial for EBV in infecting host cells. Further, by blocking CR2 
binding domain of gp350/220 using antibody will inhibit EBV’s spreading, and provoke an immune system to eliminate the virus 
in a patient. Glycoprotein 350/220 from all variants of Epstein-Barr virus was retrieved from NCBI. The conserved domain of 
gp350/220 was identified by aligning the protein sequences and structures. The polymorphic structure was used as a template for 
docking analysis to identify the resemblance of amino acid from polymorphic variants of  gp350/220 that binds CR2. The epitope 
mapping of gp350/220 was done by Discotope BepiPred method. The result revealed that the conserved region of gp350/220 was 
predicted to have an epitope, QNPVYLIPETVPYIKWDNC residue, and it does not have any similarities to the human’s cell surface 
protein. Therefore, it can be used as a reference to develop vaccine to prevent NPC. 
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Background: 
Epstein-Barr virus (EBV) is a human gamma herpes virus 
carried by more than 90% of adult population. Most individuals 
are infected asymptomatically during childhood, but a delayed 
primary infection may manifest acutely [1]. It can be associated 
with the development of epithelial malignancies, most notably 
nasopharyngeal carcinoma (NPC) [2]. EBV viral structure 
consists of linear double-stranded DNA genome, toroid shaped, 
a layer of tegument, and sheath. The sheath is out of the bulges 
(spike) composed by glycoproteins [3, 4]. 
 
BLLF1 gene encodes gp350/220 envelope glycoprotein, which 
is considered as an important antigen of EBV [5]. The 
glycoprotein binds the cellular receptor CR2 mediated EBV to 
enter the host cell [6]. The gp350/220 is an extensively 
glycosylated polypeptide (907 residues) which is expressed in 
two alternatively spliced forms of 350 and 220 kDa, identified as 
the dominant protein in the extracellular of virus’ envelope[7]. 
The N-terminal 470 residues of protein are essential to bind 
human cellular receptor, CR2. Moreover, three-dimensional 
structure of the CR2 receptor binding domain of gp350 has 
recently been determined by x-ray crystallography. 
Furthermore, we examined the conserved domain of gp350 
which was responsible for binding CR2 receptor.  
 
The conserved domain is crucial for EBV to infect host cells. BIOINFORMATION  open access 
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Further, blocking CR2 binding domain of gp350 using antibody 
will inhibit EBV’s spreading, and provoke immune system to 
eliminate the virus in a patient. Therefore, we also identified 
residues of the conserved domain which has high antigenicity 
and epitope’s properties which can be used as a reference to 
develop NPC vaccine. Epitope prediction tools have facilitated 
the vaccines development and have been applied to predict 
epitopes in viruses [8]. 
 
Methodology: 
Retrieval of Protein Sequences 
The glycoproteins 350/220 from all variants of Epstein-Barr 
virus were retrieved from the National Center of Biotechnology 
Information (www.ncbi.nlm.nih.gov). 
 
Identification of conserved domain of gp350/220 
The conserved domain of gp350/220 was identified by aligning 
protein sequences and structures, both in two dimensions (2D) 
and three dimensions (3D). The alignments were done 
separately for different types of proteins based on their 
structure.  Alignment protein sequences were performed by 
Clustal-W using MEGA 5.05 software to identify the 
polymorphism of N-terminal of protein in resides 1 to 470. 
Hereafter, the polymorphic residues were aligned by Psipred 
V2 software (http://dialign-sec.gobics.de/submission) to 
identify their similar structure in 2D format. Then polymorphic 
sequences were analyzed for their 3D structure profiles. The 3D 
structures were modeled by Swiss Model software 
(http://swissmodel.expasy.org),  and then they were aligned 
with their structure by pymol. Further, the polymorphic 
structure was used as a template for docking analysis to 
identify the resemblance of amino acid from polymorphic 
variants of gp350/220 which is responsible for binding CR2 
receptor. Protein docking is done by using ClusPro software 
(http://cluspro.bu.edu/login.php). Then the evaluation of 
docking result to analyze amino acids that bind CR2 receptor 
was done by using KFC2 (Knowledge-based FADE Contact, 
website address: http://kfc.mitchell-lab.org).  
 
Analysis of Antigenicity 
Antigenicity analysis was performed by CLC Protein 
Workbench 5.3 software 
(http://www.softepic.com/windows/graphic-apps/cad/ 
CLC-Protein-Workbench). This step is important to identify the 
antigenicity of gp350/220 residues which are responsible for 
binding CR2 receptor. Peptide sequences with high antigenicity 
properties or very antigenic ones are mandatory requirements 
to be developed into a vaccine. 
 
Figure 1: Protein gp350/220 by Swiss Model 
Epitope Mapping and BLAST Analysis 
The epitope mapping of gp350/220 was done by using 
D i s c o t o p e  B e p i P r e d  t o o l  f r o m  I m m u n e  E p i t o p e  D a t a  B a s e  
(http://www.immuneepitope.org). The obtained epitope from 
previous step was examined to see their similarity to the human 
protein sequences in Gene Bank database by using BLAST tools 
(http:// blast.ncbi.nlm.nih.gov/Blast.cgi).  This analysis was 
used to assess the similarity of epitope with the human’s 
surface cell protein. The epitope with a high similarity to 
surface cell protein has potential inducing autoimmune disease 
when it is injected to human as vaccine. 
 
Discussion: 
The EBV envelope gp350/220 protein has 907 amino acid 
residues, and N-terminal of 470 protein residues essential for 
binding CR2 receptor. Then, we identified the polymorphism of 
residues among all EBV variants from gene bank data base 
(NCBI). Here we found that among 259 variants of gp350/220, 
there were 21 sequence variants or polymorphic. Hereafter, the 
variants were aligned to their 2D structures using Psipred tools 
to determine whether these variants have a similarity in 2D 
structure. The results revealed that the variants developed 14 
different 2D structures. It means that although the protein 
sequences have 21 variants, some sequences are the same in 2D 
structure. Psipred is a very accurate method to predict the 2D 
structure of a protein. Hence, we performed further analysis by 
using three-dimensional alignment to determine whether these 
14 variants also have a similarit y  i n  3 D  s t r u c t u r e .  T h e n  w e  
predicted these 3D structure based on the homology modeling 
by referring to the atomic model of amino acid sequence and 
structure of three-dimensional (3D)-related protein homolog 
using the Swiss Model tools. Based on these predictions, we 
used a single protein sequence derived from sequences of 
HHV4 (Human Herpes Virus 4; PDB ID:2H6O) as a template. 
Modeling results demonstrated that all models, residues 4-427, 
have high similarity (from 97, 4% until 100%) in 3D structure 
(Figure 1), and they are only different in their side chain. These 
data suggested the residues formed conserved domain to 
maintain its ability to bind CR2 receptors.  
 
Figure 2: Interaction between gp350/220 and CR2 receptor. The 
interactions were predicted by protein Docking using ClusPro. 
CR2 receptor binds D2 and D1 of gp350/220. D1=domain 
1(red), D2=domain 2(yellow), D3=domain 3(magenta). 
 
Furthermore, we examined the binding ability of 3D structures 
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used CR2 receptors were obtained from PDB Bank (ID: 1LY2). 
Docking results indicated that the binding site of gp350/220 to 
CR2 receptor was located in domain 1 and domain 2 and the 
energy binding is -899.9 KJ/mol (Figure 2). The molecular 
docking is either to achieve an optimal form of protein 
conformation and that of ligand orientation or to identify the 
lowest energy which is needed to bind protein and ligand [9-
11].  
 
Figure 3: The amino acid residues of gp350/220 bind CR2 
receptor (visualized by Pymol). 
 
Therefore, we evaluated the docking results by KFC2 software 
(Knowledge-based FADE Contact) to observe amino acid 
sequence of gp350/220 which interacts with CR2 receptor. The 
analysis indicated that there were 46 amino acids of gp350/220 
involved for binding CR2 receptor. Among these amino acids, 
there are residues namely number 18, 148,160,161 and 210 
which were conserved for all variants, so the residues can be 
considered as the main domain responsible to bind CR2 
receptors (Figure 3). KFC2 is website-based software providing 
tool to predict hot spots of residues in most proteins which bind 
other surface proteins. Interactions between two proteins are 
important to elucidate geometric properties of two different 
protein structures which can be combined into complex 
structures [12]. 
 
Figure 4: Antigenicity of N-terminus gp 350/220 
Antigenicity is an ability of an antigen to specifically bind a 
particular product of antibody or T cell receptor. The 
antigenicity characterization of gp350/220 residues using CLC 
Protein Workbench 6.3 software demonstrated that all variants 
have a similar antigenic profile and the residues are important 
for binding CR2 receptor which has high antigenicity properties 
(Figure 4). The antigenicity value is calculated from the 
difference between the two data sets are used and these values 
are useful to predict the length of antigenic amino acids [13]. 
 
Figure 5:  Predicted Epitope on gp350/220 (red color) was 
visualized by Pymol. 
 
To evaluate the antigenic region of gp350/220 acting as an 
epitope, then we performed an epitope mapping of residues by 
using Discotope BepiPred, IEDB (Immune epitope Database). 
The data revealed that the region was predicted to contain an 
epitope which is suitable for a vaccine, 19-mer 
QNPVYLIPETVPYIKWDNC residue (Figure 5). Thereafter, we 
analyzed the similarity of the epitope with human’s cell surface 
protein to avoid cross reactivity of antibody when the region 
was applied as vaccine. The similarity identification was done 
by aligning the epitope sequence to human protein data bank in 
NCBI by using BLAST tool. The result informed that the 
epitope does not have a similarity with the human’s cell surface 
protein, so the epitope can be used as a reference to develop a 
vaccine to prevent nasopharyngeal carcinoma (NPC). This high 
antigenicity epitope is warranted to be tested as an antigen for 
peptide vaccine. It corresponds with the previous study 
showing that high antigenicity epitope regions could be 
designed as a vaccine candidate [8]. Moreover, this study 
demonstrated that bioinformatics is a useful tool to design 
vaccine for cancer, and another study also showed the 
bioinformatics is also helpful to analyze gene-gene interaction 
and pathway analysis of cancer cells death mediated by herbal 
extract [14]. 
 
Conclusion: 
It could be concluded from this study that the residue 147-165 
of gp350/220, QNPVYLIPETVPYIKWDNC, was predicted as a 
high antigenicity epitope which is responsible for binding to 
CR2 receptor. The residue is promising to be developed as a 
vaccine candidate to prevent NPC. 
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